PATENT CLAIM ANALYSIS

Application Number: 15873416
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-12
Patent Classification: ["514", "001100"]

Abstract:
The disclosure provides compositions and methods for counteracting the effects of direct activated Factor X (FXa) inhibitors in a subject by administering a variant of FXa.

Claim (Index 35):
The method of  claim 42 , wherein the plasma concentration of api-xabanthe direct FXa inhibitor is at least about 50 nM, 100 nM, 150 nM, 200 nM, 250 nM, 300 nM, 350 nM, 400 nM, 500 nM, 600 nM, 700 nM, or 800 nM.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 86.0
- Lexical Diversity: 1.11538
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12616735', '13414499', '13889014', '12239651', '13591098']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8020044390391284
- 35 USC 102 Novelty (BERT): 0.5252778829377367
- Combined Prediction Score: 0.7743317834289893
- Mean Citation Score: 318.84791800000005
- Max Citation Score: 322.3307200000001
- Similarity Product: 202.2724972712899

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test